A Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation
Phase of Trial: Phase I/II
Latest Information Update: 01 Jun 2017
Price : $35 *
At a glance
- Drugs Udenafil (Primary)
- Indications Congenital heart defects; Ventricular dysfunction
- Focus Adverse reactions
- Sponsors Mezzion
- 26 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Mar 2015 A preliminary review of results was positive, according to a Mezzion Pharma media release.
- 04 Aug 2014 New trial record